A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery
A new technology has been developed that allows human antibodies to be quickly generated against virtually any antigen. Using a novel process, naïve human B cells are isolated from tonsil tissue and transformed with efficiency up to 85%, thus utilizing a large portion of the human VDJ/VJ repertoire....
Gespeichert in:
| Veröffentlicht in: | mAbs 2011-03, Vol.3 (2), p.203-208 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 208 |
|---|---|
| container_issue | 2 |
| container_start_page | 203 |
| container_title | mAbs |
| container_volume | 3 |
| creator | Duvall, Marcus Bradley, Norma Fiorini, Ryan N |
| description | A new technology has been developed that allows human antibodies to be quickly generated against virtually any antigen. Using a novel process, naïve human B cells are isolated from tonsil tissue and transformed with efficiency up to 85%, thus utilizing a large portion of the human VDJ/VJ repertoire. Through ex vivo stimulation, the B cells class switch and may undergo somatic hypermutation, thus producing a human “library” of different IgG antibodies that can then be screened against any antigen. Since diversity is generated ex vivo, sampling immunized or previously exposed individuals is not necessary. Cells producing the antibody of interest can be isolated through limiting dilution cloning and the human antibody from the cells can be tested for biological activity. No humanization is necessary because the antibodies are produced from human B cells. By eliminating immunization and humanization steps, and screening a broadly diverse library, this platform should reduce both the cost and time involved in producing therapeutic monoclonal antibody candidates. |
| doi_str_mv | 10.4161/mabs.3.2.14774 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_lande</sourceid><recordid>TN_cdi_landesbioscience_primary_mabs_article_14774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21285537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-bd923c2265bb24ddb5b1af3988be60ec33f3c079b0687cea6343d68beb9f375f3</originalsourceid><addsrcrecordid>eNqNUU1v1DAQtRCIVqVXjsh_YIM_kjjhgLSUT6mIA-Vs-WPcNXLsyHZW9Mg_J9stK7gg5jIzmvfejOYh9JySpqU9fTkpXRresIa2QrSP0DkdW7YhgyCPT3XPztBlKd_JIQShgjxFZ4yyoeu4OEc_tzimPQQ8B1VdyhOuCc852cUA3i2TinhKMZmQogpYxep1sh7KK3yzAxzhR8W3ECGr6lPEyeG6W5sZlurNv_jY-mLWxfnuGXriVChw-ZAv0Lf3726uPm6uv3z4dLW93piW8brRdmTcMNZ3WrPWWt1pqhwfh0FDT8Bw7rghYtSkH4QB1fOW234d6tFx0Tl-gV4fdedFT2ANxJpVkHP2k8p3Mikv_55Ev5O3aS85GVnP6CrQHAVMTqVkcCcuJfLghzz4Iblk8t6PlfDiz40n-O_vrwB2BAQVLRTtUzEeooET9O2yVyHIz9s3Xw-6s3X_Qbo_Q-XVgQAPp_wCSj2xXw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Duvall, Marcus ; Bradley, Norma ; Fiorini, Ryan N</creator><creatorcontrib>Duvall, Marcus ; Bradley, Norma ; Fiorini, Ryan N</creatorcontrib><description>A new technology has been developed that allows human antibodies to be quickly generated against virtually any antigen. Using a novel process, naïve human B cells are isolated from tonsil tissue and transformed with efficiency up to 85%, thus utilizing a large portion of the human VDJ/VJ repertoire. Through ex vivo stimulation, the B cells class switch and may undergo somatic hypermutation, thus producing a human “library” of different IgG antibodies that can then be screened against any antigen. Since diversity is generated ex vivo, sampling immunized or previously exposed individuals is not necessary. Cells producing the antibody of interest can be isolated through limiting dilution cloning and the human antibody from the cells can be tested for biological activity. No humanization is necessary because the antibodies are produced from human B cells. By eliminating immunization and humanization steps, and screening a broadly diverse library, this platform should reduce both the cost and time involved in producing therapeutic monoclonal antibody candidates.</description><identifier>ISSN: 1942-0862</identifier><identifier>EISSN: 1942-0870</identifier><identifier>DOI: 10.4161/mabs.3.2.14774</identifier><identifier>PMID: 21285537</identifier><language>eng</language><publisher>United States: Landes Bioscience</publisher><subject>Antibodies, Monoclonal - biosynthesis ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - therapeutic use ; Antigens - immunology ; B-Lymphocytes - cytology ; B-Lymphocytes - immunology ; Binding ; Biology ; Bioscience ; Biotechnology - methods ; Brief Report ; Calcium ; Cancer ; Cell ; Cell Transformation, Viral ; Cycle ; Herpesvirus 4, Human - physiology ; Humans ; Immunoglobulin Class Switching ; Immunoglobulin G - biosynthesis ; Immunoglobulin G - immunology ; Landes ; Leukocytes, Mononuclear - cytology ; Leukocytes, Mononuclear - immunology ; Mutation ; Organogenesis ; Palatine Tonsil - cytology ; Palatine Tonsil - immunology ; Proteins</subject><ispartof>mAbs, 2011-03, Vol.3 (2), p.203-208</ispartof><rights>Copyright © 2011 Landes Bioscience 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c423t-bd923c2265bb24ddb5b1af3988be60ec33f3c079b0687cea6343d68beb9f375f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092621/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092621/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21285537$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Duvall, Marcus</creatorcontrib><creatorcontrib>Bradley, Norma</creatorcontrib><creatorcontrib>Fiorini, Ryan N</creatorcontrib><title>A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery</title><title>mAbs</title><addtitle>MAbs</addtitle><description>A new technology has been developed that allows human antibodies to be quickly generated against virtually any antigen. Using a novel process, naïve human B cells are isolated from tonsil tissue and transformed with efficiency up to 85%, thus utilizing a large portion of the human VDJ/VJ repertoire. Through ex vivo stimulation, the B cells class switch and may undergo somatic hypermutation, thus producing a human “library” of different IgG antibodies that can then be screened against any antigen. Since diversity is generated ex vivo, sampling immunized or previously exposed individuals is not necessary. Cells producing the antibody of interest can be isolated through limiting dilution cloning and the human antibody from the cells can be tested for biological activity. No humanization is necessary because the antibodies are produced from human B cells. By eliminating immunization and humanization steps, and screening a broadly diverse library, this platform should reduce both the cost and time involved in producing therapeutic monoclonal antibody candidates.</description><subject>Antibodies, Monoclonal - biosynthesis</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antigens - immunology</subject><subject>B-Lymphocytes - cytology</subject><subject>B-Lymphocytes - immunology</subject><subject>Binding</subject><subject>Biology</subject><subject>Bioscience</subject><subject>Biotechnology - methods</subject><subject>Brief Report</subject><subject>Calcium</subject><subject>Cancer</subject><subject>Cell</subject><subject>Cell Transformation, Viral</subject><subject>Cycle</subject><subject>Herpesvirus 4, Human - physiology</subject><subject>Humans</subject><subject>Immunoglobulin Class Switching</subject><subject>Immunoglobulin G - biosynthesis</subject><subject>Immunoglobulin G - immunology</subject><subject>Landes</subject><subject>Leukocytes, Mononuclear - cytology</subject><subject>Leukocytes, Mononuclear - immunology</subject><subject>Mutation</subject><subject>Organogenesis</subject><subject>Palatine Tonsil - cytology</subject><subject>Palatine Tonsil - immunology</subject><subject>Proteins</subject><issn>1942-0862</issn><issn>1942-0870</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUU1v1DAQtRCIVqVXjsh_YIM_kjjhgLSUT6mIA-Vs-WPcNXLsyHZW9Mg_J9stK7gg5jIzmvfejOYh9JySpqU9fTkpXRresIa2QrSP0DkdW7YhgyCPT3XPztBlKd_JIQShgjxFZ4yyoeu4OEc_tzimPQQ8B1VdyhOuCc852cUA3i2TinhKMZmQogpYxep1sh7KK3yzAxzhR8W3ECGr6lPEyeG6W5sZlurNv_jY-mLWxfnuGXriVChw-ZAv0Lf3726uPm6uv3z4dLW93piW8brRdmTcMNZ3WrPWWt1pqhwfh0FDT8Bw7rghYtSkH4QB1fOW234d6tFx0Tl-gV4fdedFT2ANxJpVkHP2k8p3Mikv_55Ev5O3aS85GVnP6CrQHAVMTqVkcCcuJfLghzz4Iblk8t6PlfDiz40n-O_vrwB2BAQVLRTtUzEeooET9O2yVyHIz9s3Xw-6s3X_Qbo_Q-XVgQAPp_wCSj2xXw</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Duvall, Marcus</creator><creator>Bradley, Norma</creator><creator>Fiorini, Ryan N</creator><general>Landes Bioscience</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20110301</creationdate><title>A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery</title><author>Duvall, Marcus ; Bradley, Norma ; Fiorini, Ryan N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-bd923c2265bb24ddb5b1af3988be60ec33f3c079b0687cea6343d68beb9f375f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antibodies, Monoclonal - biosynthesis</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antigens - immunology</topic><topic>B-Lymphocytes - cytology</topic><topic>B-Lymphocytes - immunology</topic><topic>Binding</topic><topic>Biology</topic><topic>Bioscience</topic><topic>Biotechnology - methods</topic><topic>Brief Report</topic><topic>Calcium</topic><topic>Cancer</topic><topic>Cell</topic><topic>Cell Transformation, Viral</topic><topic>Cycle</topic><topic>Herpesvirus 4, Human - physiology</topic><topic>Humans</topic><topic>Immunoglobulin Class Switching</topic><topic>Immunoglobulin G - biosynthesis</topic><topic>Immunoglobulin G - immunology</topic><topic>Landes</topic><topic>Leukocytes, Mononuclear - cytology</topic><topic>Leukocytes, Mononuclear - immunology</topic><topic>Mutation</topic><topic>Organogenesis</topic><topic>Palatine Tonsil - cytology</topic><topic>Palatine Tonsil - immunology</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Duvall, Marcus</creatorcontrib><creatorcontrib>Bradley, Norma</creatorcontrib><creatorcontrib>Fiorini, Ryan N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>mAbs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Duvall, Marcus</au><au>Bradley, Norma</au><au>Fiorini, Ryan N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery</atitle><jtitle>mAbs</jtitle><addtitle>MAbs</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>3</volume><issue>2</issue><spage>203</spage><epage>208</epage><pages>203-208</pages><issn>1942-0862</issn><eissn>1942-0870</eissn><abstract>A new technology has been developed that allows human antibodies to be quickly generated against virtually any antigen. Using a novel process, naïve human B cells are isolated from tonsil tissue and transformed with efficiency up to 85%, thus utilizing a large portion of the human VDJ/VJ repertoire. Through ex vivo stimulation, the B cells class switch and may undergo somatic hypermutation, thus producing a human “library” of different IgG antibodies that can then be screened against any antigen. Since diversity is generated ex vivo, sampling immunized or previously exposed individuals is not necessary. Cells producing the antibody of interest can be isolated through limiting dilution cloning and the human antibody from the cells can be tested for biological activity. No humanization is necessary because the antibodies are produced from human B cells. By eliminating immunization and humanization steps, and screening a broadly diverse library, this platform should reduce both the cost and time involved in producing therapeutic monoclonal antibody candidates.</abstract><cop>United States</cop><pub>Landes Bioscience</pub><pmid>21285537</pmid><doi>10.4161/mabs.3.2.14774</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1942-0862 |
| ispartof | mAbs, 2011-03, Vol.3 (2), p.203-208 |
| issn | 1942-0862 1942-0870 |
| language | eng |
| recordid | cdi_landesbioscience_primary_mabs_article_14774 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Antibodies, Monoclonal - biosynthesis Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antigens - immunology B-Lymphocytes - cytology B-Lymphocytes - immunology Binding Biology Bioscience Biotechnology - methods Brief Report Calcium Cancer Cell Cell Transformation, Viral Cycle Herpesvirus 4, Human - physiology Humans Immunoglobulin Class Switching Immunoglobulin G - biosynthesis Immunoglobulin G - immunology Landes Leukocytes, Mononuclear - cytology Leukocytes, Mononuclear - immunology Mutation Organogenesis Palatine Tonsil - cytology Palatine Tonsil - immunology Proteins |
| title | A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A08%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_lande&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20novel%20platform%20to%20produce%20human%20monoclonal%20antibodies:%20The%20next%20generation%20of%20therapeutic%20human%20monoclonal%20antibodies%20discovery&rft.jtitle=mAbs&rft.au=Duvall,%20Marcus&rft.date=2011-03-01&rft.volume=3&rft.issue=2&rft.spage=203&rft.epage=208&rft.pages=203-208&rft.issn=1942-0862&rft.eissn=1942-0870&rft_id=info:doi/10.4161/mabs.3.2.14774&rft_dat=%3Cpubmed_lande%3E21285537%3C/pubmed_lande%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21285537&rfr_iscdi=true |